Updated August 2026. Originally published June 2021.
In 2003, the Human Genome Project and Celera Genomics announced successful whole human genome sequencing. The achievement came with a catch, though: the sequence was 15% incomplete. Researchers solved parts of that puzzle over the following years — yet from 2013 through 2021, our reference model of the human genome still lacked 8% of the full sequence.
Two milestones since then have closed that gap entirely. In March 2022, the Telomere-to-Telomere (T2T) Consortium published the first truly complete human genome sequence in Science, filling in all 22 autosomes and the X chromosome, adding nearly 200 million base pairs of previously unknown sequence, and identifying 1,956 new gene predictions. Then in August 2023, the same consortium completed the Y chromosome — the final human chromosome to be fully sequenced — uncovering genomic features with direct implications for fertility and sperm production. The reference human genome now covers all 3.055 billion base pairs with zero gaps. As a result, every WGS result you receive today compares against a dramatically more accurate reference than was available just five years ago.
So how does whole genome sequencing benefit you?
Preventative, personalized, precision medicine (3P-M) starts with whole genome sequencing (WGS). More specifically, 3P-M requires what researchers call multi-omic biological analysis — where data sets span multiple “omes”: your genome, proteome, transcriptome, epigenome, and microbiome. Combining information across those data sets lets researchers identify potential therapeutic targets and biomarkers to prevent disease and keep you healthy.
Mayo Clinic research found that 12% of healthy people — one in eight — carry clinically actionable results, predominantly in genes tied to cardiovascular disease and cancer. Beyond that, diagnostic results from Human Longevity’s full body testing program identified a slightly higher rate of near-term actionable findings.
Setting your health baseline by measuring your DNA’s current state lets you detect how it changes over time. How should you do that? Who are the providers? What are the costs in 2026? Are they worth paying for personally? And what are the potential risks?
First, the sequencing terminology
Genotyping — the least expensive DNA service. Your genes are compared to a standard reference genome to identify single-nucleotide polymorphisms (SNPs) — variations of a single letter (base pair) of DNA. Over 660 million SNPs exist in the reference human genome (out of 3.055 billion total letters), making them the most common type of genetic variation in humans. SNPs explain traits like eye color, inherited diseases like cystic fibrosis and sickle cell anemia, and carry markers indicating risk for complex conditions like diabetes and Alzheimer’s disease.
Exome sequencing — finds medical insights that genotyping misses. Specifically, it decodes the stretches of DNA called exons that carry instructions for making functioning proteins — roughly 20,000 genes covering about 1% of your genome. This approach allows variations in the protein-coding region of any gene to be identified, not just a select few. Because most known disease-causing mutations occur in exons, whole exome sequencing efficiently surfaces possible pathogenic variants.
Whole genome sequencing — the most thorough option. In theory, it translates every letter in your genome. In practice, some regions are difficult to read, so sequencing typically runs 20, 50, or 100 times to catch errors — known as 20x, 50x, or 100x “coverage.” With the T2T reference genome now complete, the 8% gap that affected older WGS results no longer applies to the reference itself, though individual consumer tests still vary in coverage depth and analytical quality.
What’s new since the original article
The human reference genome is now complete — including the Y chromosome. The original article noted that “there is remaining work to scan the Y chromosome.” The T2T Consortium finished that work in August 2023. The result — all 3.055 billion base pairs, zero gaps — represents the most significant improvement in genomic infrastructure since the original Human Genome Project. Consequently, any WGS run today benefits from a more accurate reference than was ever previously available.
Invitae filed for bankruptcy and was acquired by Labcorp. Invitae — listed in the original article as offering cancer and cardio risk screening of 167 genes — filed for Chapter 11 bankruptcy on February 13, 2024. Labcorp then acquired most of Invitae’s assets through a bankruptcy auction for $239 million, with court approval in May 2024. Genetic testing through this platform now operates under Labcorp.
Nebula Genomics shut down in February 2025. Nebula — listed in the original as offering 30x WGS at $299 with privacy protection — shut down on February 5, 2025. Parent company ProPhase Labs filed for Chapter 11 bankruptcy in September 2025. Existing customers received a final data export window; raw VCF files downloaded before shutdown remain usable with third-party analysis tools. Nucleus Genomics and Dante Labs now lead the consumer WGS market in 2026.
WGS prices have continued to drop. Consumer 30x whole genome sequencing now runs $180–$495 depending on provider and coverage depth. At the low end, flash sale pricing at Dante Labs can reach approximately $180. Clinical-grade WGS at hospitals and reference laboratories — which includes physician ordering, variant interpretation, and a clinical report — typically costs $1,000–$5,000, and insurance covers it for appropriate clinical indications.
Genome sequencing providers (2026)
Direct-to-consumer genotyping services — 23andMe, Ancestry.com, LivingDNA, FamilyTree, and MyHeritage — remain inexpensive at $59–$99. That low price comes with serious trade-offs, however. These services only screen a small number of select biomarkers. More importantly, they own your DNA data and often sell it for commercial use. You, your current relatives, and your future relatives generally don’t want that — particularly because law enforcement can compel these companies to provide your DNA to match against crime scene evidence, potentially implicating you or your kin in ways you never consented to. Current privacy laws do not provide sufficient protection against this risk.
Private complete sequencing from reputable firms that don’t sell your information is meaningfully better. Prices continue to drop and may eventually reach zero, according to Andrew Hessel, co-founder of Humane Genomics and Chair of the Board of Genome-Project-Write.
Active consumer WGS providers in 2026:
- Dante Labs — 30x whole genome sequencing at approximately €399 (~$430 USD) standard, with flash sales dropping to approximately €169 (~$180) three to four times per year. The package includes 200+ clinical reports via their Genome Manager platform with lifetime updates. Several caveats apply, though: the Better Business Bureau rates their customer support “F,” turnaround times run 8–12 weeks per user reports, and some customers report delayed kit shipments. Download your raw data files immediately upon receipt — user reports suggest Dante has occasionally removed download links after 12–18 months. On the positive side, raw data (FASTQ/BAM/VCF) is included at no extra charge.
- Nucleus Genomics — 30x WGS at $399 plus $39/year for ongoing report updates. Nucleus emerged as one of the leading active WGS providers following Nebula’s closure. The platform emphasizes privacy-first design and polygenic risk score reporting.
- Sequencing.com — tiered pricing from 1x screening ($195) to 30x clinical ($495) and up to 100x ultra-deep. The platform operates an app marketplace where third-party analysis tools apply to your raw data. Worth noting: individual apps cost extra — from $0 to $399 each — so comprehensive reporting can push total cost well above competitors’ all-inclusive pricing. On the other hand, Sequencing.com accepts raw VCF files from other providers, including former Nebula customers.
- Full Genomes — 30x sequencing plus Y chromosome, with pricing on their site. Adding $75 unlocks analysis including ancestry.
- SelfDecode — SNP-based analysis platform, not full WGS. The service analyzes 83 million SNPs using uploaded data at $199 standard or $499 premium. It works best as an analysis layer on top of WGS data from another provider. Unlike simpler genotyping reports that examine a handful of variants per trait, SelfDecode’s polygenic risk score models analyze hundreds of thousands of variants.
Clinical WGS (physician-ordered):
- Labcorp (formerly Invitae) — genetic testing including cancer and cardio risk screening, now operating under Labcorp following the 2024 acquisition. Physician-ordered; covered by insurance for appropriate clinical indications.
- Veritas Genetics — physician-ordered WGS; pricing varies by order type.
A note on privacy: Dante Labs sends samples to its lab in Italy. Nucleus Genomics and Sequencing.com operate with stated privacy-first architectures. Regardless of provider, read the privacy policy before submitting a sample — look specifically for whether your data can be shared with third parties, sold, or provided to law enforcement without your direct consent.
Leading sequencing technology platforms
- 10X Genomics — determines gene expression within cells and across cell populations.
- GeneDx — handles the majority of WGS clinical sequencing for physicians in the US.
- Illumina‘s NovaSeq X — Illumina’s current flagship short-read platform for WGS at scale, succeeding the NovaSeq 6000 mentioned in the original article.
- Oxford Nanopore Technologies — MinION portable DNA sequencer that reads DNA in real time. Its long-read technology played a central role in the T2T consortium’s Y chromosome sequencing.
- Pacific Biosciences — HiFi long-read sequencing that co-produced the T2T reference genome alongside Oxford Nanopore. The technology reads 20,000 DNA letters at a time, making gap-free reference assembly possible.
- Thermo Fisher Scientific’s Ion Torrent — covers whole genome, exome, and transcriptome sequencing.
How to use your whole genome sequencing results
Your DNA readout arrives in several formats. A sequencing machine first produces a FASTQ file — long strings of letters representing raw reads. Those fragments are then reassembled into a SAM (Sequence Alignment/Map) or BAM (Binary Alignment/Map) file, which various DNA analysis services can process. From there, those services generate a variant call format (VCF) file that compares your DNA against the reference genome and flags what is unique to you. Because large text files aren’t readable without interpretation, software tools are essential for surfacing what is meaningful and actionable.
Analysis tools and resources:
- Guide to Genetic Testing — “I got my genetic results. Now what?” Published by the National Human Genome Research Institute (NHGRI).
- GeneCards — searchable library of everything known about each human gene. See this example for how detailed individual gene entries can be.
- MyGeneRank — app to assess risk of polygenic events.
- GenBank — the NIH genetic sequence database, an annotated collection of all publicly available DNA sequences.
- Sequencing.com’s Genome Explorer — upload your genome file and apply their marketplace of analysis apps.
- SelfDecode ($97/year, $297 lifetime) — upload your genome data and analyze it across hundreds of health traits. An independent review includes a discount code.
- Promethease — a $12 literature mining tool that compares your genome against SNPedia, a curated database of published genetic variant research. Many people use it as a first step after receiving raw WGS data.
Interesting longevity gene research
- Longevity Genes Project — seeks to identify protective genes in centenarians. Led by Nir Barzilai at the Albert Einstein College of Medicine, the same researcher driving the TAME trial on metformin.
- Dialing down the “grim reaper” gene — on insulin-growth factor 1 (IGF-1) and its role in longevity.
- Gene for healthy aging in worms — and its potential implications for humans.
- Atum Biosciences — designs and manufactures synthetic genes and proteins for research. Their free tool GeneDesigner 2.0 lets you explore gene design directly.
- Risks of uncontrolled gene editing — a useful counterweight to the enthusiasm around DIY genomics and self-administered gene therapies.
For deeper coverage of how genetic discoveries translate into longevity applications, see Keep Health’s articles on Reversing Aging, Cellular Reprogramming, and Genetic Longevity.
Should you get sequenced?
Getting your genome sequenced is a one-time investment that generates a lifetime of increasingly useful information. The data you produce today will become more valuable — not less — as research uncovers new variants associated with disease risk, drug response, and longevity. That’s the argument for doing it now rather than waiting for prices to fall further: the genome doesn’t change, but our understanding of what it means keeps improving.
That said, the risks are real. Genetic information can affect life insurance and disability insurance eligibility in ways that health insurance cannot. The Genetic Information Nondiscrimination Act (GINA) does not cover life or disability insurance, so those policies remain unprotected. Beyond that, privacy protections vary by provider and are weaker than most people assume. Finally, clinically actionable results — the one-in-eight finding from the Mayo Clinic research — sometimes surface conditions that require difficult decisions. For that reason, most providers now recommend or require a genetic counselor consultation when pathogenic variants are found.
For further context on where WGS fits into a broader health picture, see Keep Health’s Biological Age Tests, Measuring Your Biological Health, and Setting Your Health Baseline articles.
As your reward for focusing on your health today, here is an astonishing milestone in DNA research. In February 2021, researchers announced they had found and sequenced DNA from a million-year-old steppe mammoth. For comparison, the oldest sequenced human DNA dates from a mere 430,000 years ago. If the possibility of recreating mammoths in the modern world intrigues you, Beth Shapiro’s 2015 book How to Clone a Mammoth: The Science of De-Extinction covers exactly that subject.
